Please note…

You are now on the ey.com Global site. To return to the ey.com United States site or other country site, click on the Global (English) link on the upper right of this page, and select your preferred country site.

x
Skip to main navigation

Ernst & Young Global Pharmaceutical Center - Ernst & Young - Global

  • Share

Helping you map the right way forward

Pharmaceutical companies are facing great changes to the industry — emerging science, new products and services, shifting demographics, evolving regulations, transforming business models and increased stakeholder expectations. We are helping pharmaceutical companies around the globe to address the challenges presented by these changes.

Through the Ernst & Young’s Global Life Science Center, we bring together a worldwide team of industry professionals to help you achieve your potential — a team with deep experience in providing assurance, tax, transaction and advisory services to pharmaceutical companies around the globe. It’s a team that works to anticipate market trends and their implications, so you receive practical advice on the right way forward for your organization.We also publish a series of reports to bring you clear insights on accounting, tax, transaction, compliance and business process issues specific and often unique to the biotech sector, as well as our annual report on pharmaceutical industry trends, Progressions. Our thought leadership helps you navigate the shifting global landscape and grow your business — the business of improving people's health.

Whether it’s forming the right alliances, addressing the changing pharmaceutical business model, improving operations, enhancing your reputation or gaining insights into the market, we can give you a clear perspective on how to drive value in today’s complex, competitive and risk-driven environment.

The cost of life in an aging world

Increasing life spans have led the pharmaceutical industry to ask new questions about the role of preventative medicine and the cost of innovation. We explore.

Progressions 2011: Building Pharma 3.0

A transformation of the pharmaceutical industry is underway as companies begin shifting from producing new medicines to demonstrating improved health outcomes. No longer the dominant health care player, pharma has a new focus. We report on pharma’s progress in creating new business models and partnerships focused on technology and sustainability.

Progressions: Pharma 3.0 — pharmaceutical report 2010

The industry is morphing into a new ecosystem, one we call Pharma 3.0. The focus is shifting from developing drugs to delivering "healthy outcomes." And nontraditional companies —mobile telecom, IT, food, retail, etc. — are sweeping into the sector. Is your company ready? Here are our insights on how to prosper.

Cash on prescription: pharmaceutical companies and working capital

Pharmaceutical companies in the US and Europe improved working capital performance in 2010 compared with 2009. Was this improvement enough to reverse the previous deterioration?

Progressions 2012: health care everywhere

Disruptive innovations and unsustainable costs are propelling life sciences companies into the behavioral change business. Learn why in our annual life sciences report

young researcher

News

Events

Contacts

Watch the Pharma 3.0 webcast 1 minute recap

Webcast: Pharma 3.0: meeting the challenge 
View a recap of our latest Pharma 3.0 discussion. Can your life sciences company improve its communications with payers and practitioners?

Six global trends shaping the business world

How will pharma develop in 2011 and beyond? From the growing power of emerging markets to rapid innovations in technology, see which global trends and drivers are likely to shape the future of your business.

Industry segments we serve

  • Large pharma
  • Drug wholesalers
  • Clinical research organizations
  • Pharmacy benefit management companies

Back to top